Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
3.720
+0.060 (1.64%)
Oct 8, 2025, 2:25 PM EDT - Market open
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$65,250
Profits / Employee
-$922,264
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVB News
- 8 days ago - Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire
- 9 days ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 19 days ago - Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 23 days ago - Nuvation Bio: A Rare Gem In The Risky Biotech Space - Seeking Alpha
- 4 weeks ago - Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer - Business Wire
- 4 weeks ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga
- 5 weeks ago - Nuvation Bio: What To Expect From IBTROZI Launch? - Seeking Alpha
- 5 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire